[Retracted] Treatment Protocols in the Efficacy and Safety of Anti-EGFR Medicines in Combination with Standard Therapy for Patients with Nasopharyngeal Cancer: A Meta-Analysis

Table 1

Characteristics of included studies.

Author (yr)	Age (years), median (range)		Median follow-up
	Anti-EGFR	Control	Anti-EGFR	Control
Wu (2014)	36 (26-57)	47 (32-63)	RT+h-R3	RT
Mei (2018)	45 (25-68)	44 (15-67)	CTX/NTX+CCRT	IC+CCRT
You (2017)	45 (12-69)	46 (15-74)	CTX/NTX+CCRT	CCRT
Mao (2019)	44 (17-72)	43 (13-73)	NTX/CTX+CRT	CRT
Hao (2018)	42 (36-51)	44 (36-51)	CTX/NTX+IC	IC
Wu (2007)	36 (26-57)	47 ()	RT+h-R3	RT
Wang (2019)	44 (34-55)	44 (32-55)	NTZ+IMRT	IMRT
Li (2016)	60 (25-68)	60 (25-67)	RT+h-R3	RT+CDDP
Xia (2017)	44 (32-52)	44 (32-52)	CTX+CCRT	CCRT
Yang (2017)	46 (25-64)	46 (28-66)	CTX+CCRT	CCRT
You (2017)	46 (18-75)	47 (15-74)	CTX/NTX+IMRT	IMRT+CDDP

Note: anti-EGFR: anti-epidermal growth factor receptor. CTX; NTX; h-R3; IMRT; CDDP.